{"id":"duostim","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DUOSTIM employs simultaneous stimulation with follicle-stimulating hormone (FSH) and luteinizing hormone (LH) to promote multiple follicle development during in vitro fertilization cycles. This dual-hormone approach aims to improve oocyte yield and embryo quality compared to FSH-alone protocols, particularly in poor responders or women of advanced reproductive age.","oneSentence":"DUOSTIM is a dual stimulation protocol combining FSH and LH for controlled ovarian hyperstimulation in assisted reproductive technology.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:17.107Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Controlled ovarian hyperstimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF)"},{"name":"Ovulation induction in infertility treatment"}]},"trialDetails":[{"nctId":"NCT05815719","phase":"PHASE4","title":"Continuous Double Ovarian Stimulation.","status":"COMPLETED","sponsor":"Instituto Bernabeu","startDate":"2022-11-17","conditions":"Fertility Issues","enrollment":30},{"nctId":"NCT06799598","phase":"","title":"DUOSTIM and AI: is There a Difference Between Oocyte Performance in the Follicular and Luteal Phases?","status":"COMPLETED","sponsor":"Rio de Janeiro State University","startDate":"2024-05-01","conditions":"Infertility","enrollment":92},{"nctId":"NCT06637189","phase":"PHASE4","title":"Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.","status":"NOT_YET_RECRUITING","sponsor":"Ginefiv","startDate":"2024-10-15","conditions":"Stimulation in the Ovary, Embryo, Oocyte","enrollment":144},{"nctId":"NCT06199960","phase":"PHASE3","title":"Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2019-08-02","conditions":"Assisted Reproductive Techniques","enrollment":116},{"nctId":"NCT04531644","phase":"NA","title":"Double Stimulation in Women With Low Prognosis in ART","status":"UNKNOWN","sponsor":"Tu Du Hospital","startDate":"2020-05-14","conditions":"Assisted Reproductive Techniques","enrollment":100},{"nctId":"NCT06093984","phase":"NA","title":"Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders","status":"NOT_YET_RECRUITING","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2023-11-01","conditions":"Infertility","enrollment":260},{"nctId":"NCT03803228","phase":"PHASE3","title":"Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2018-09-03","conditions":"Fertility Disorders","enrollment":88},{"nctId":"NCT05321511","phase":"PHASE4","title":"Comparison of Triggers in Double Ovarian Stimulation (DuoStim).","status":"UNKNOWN","sponsor":"Instituto Bernabeu","startDate":"2022-03-03","conditions":"IVF, LOW OVARIAN RESPONSE","enrollment":165},{"nctId":"NCT03291821","phase":"NA","title":"DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2017-12-01","conditions":"Infertility, Female","enrollment":136},{"nctId":"NCT03400722","phase":"PHASE4","title":"Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response","status":"UNKNOWN","sponsor":"Nova Clinic, Russia","startDate":"2017-12-01","conditions":"Infertility, Female, Ovarian Stimulation, In Vitro Fertilisation","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":73,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Same monthly cycle"],"phase":"phase_3","status":"active","brandName":"DUOSTIM","genericName":"DUOSTIM","companyName":"Centre Hospitalier Intercommunal Creteil","companyId":"centre-hospitalier-intercommunal-creteil","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DUOSTIM is a dual stimulation protocol combining FSH and LH for controlled ovarian hyperstimulation in assisted reproductive technology. Used for Controlled ovarian hyperstimulation in assisted reproductive technology (ART) / in vitro fertilization (IVF), Ovulation induction in infertility treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}